According to research by SNS Insider, the global osteoporosis treatment market growth is driven by rising osteoporosis prevalence, expanding access to biologics, and advancing treatment innovation.
Austin, Dec. 01, 2025 (GLOBE NEWSWIRE) — According to SNS Insider, The Osteoporosis Treatment Market size was valued at $15.73 billion in 2024 and is expected to reach $20.99 billion by 2032 and grow at a CAGR of 4.83% over 2025-2032. The U.S. osteoporosis treatment market size was valued at $4.80 billion in 2024 and is expected to reach $6.24 billion by 2032, growing at a CAGR of 4.49% over 2025-2032.
Due to the high incidence of osteoporosis, particularly in elderly and postmenopausal patients, the U.S. holds a dominant position in the market analysis of osteoporosis treatments in North America.
Get a Sample Report of Osteoporosis Treatment Market: https://www.snsinsider.com/sample-request/3337
Rising Incidence of Osteoporotic Fractures is Driving the Market Expansion Globally
The frequency of osteoporotic fractures, notably those of the hip, spine, and wrist, is rising worldwide, especially among the elderly and postmenopausal. These fractures are widespread, often occur after minor trauma, and increase immobility, disability, and mortality. There is a growing need for preventative care and treatments that will strengthen bones and lower the risk of osteoporosis because fracture risk rises with age and is even linked to osteoporosis. One major factor propelling the market for osteoporosis treatments is this clinical necessity.
Key Osteoporosis Treatment Companies Profiled in the Report
- Amgen Inc.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc
- Radius Health Inc.
- Mitsubishi Tanabe Pharma Corporation
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Zydus Lifesciences Ltd.
- Cipla Ltd.
- Intas Pharmaceuticals Ltd.
- Aurobindo Pharma Ltd.
- Apotex Inc.
- Gedeon Richter Plc.
- Hanmi Pharmaceutical Co. Ltd.
- Other Key Participants
Segmentation Analysis:
By Drug Class
Bisphosphonate segment dominated the osteoporosis treatment market share in 2024 with around 28.5%, owing to its long-standing use, low cost, and well-established clinical benefits in reducing fractures. The hormone replacement therapy (HRT) segment is expected to grow at the fastest rate during the forecast period. This growth is being driven by the growing interest in postmenopausal health management, the increased awareness of estrogen’s protective effects on bone mass, and new HRT formulations designed to mitigate risks.
By Route of Administration
Parenteral segment dominated the osteoporosis treatment market with a 76.3% market share in 2024 on account of growing acceptance of injectable drugs, which provide better compliance and efficacy. The oral segment is expected to register the highest CAGR during the forecast period due to an increase in the demand for non-invasive therapies that can be self-administered.
By Gender
The female segment led the osteoporosis treatment market share with a 66.4% in 2024, on account of a substantially higher incidence of osteoporosis in women, particularly those women who have passed menopause. The female segment will remain the fastest-growing segment over the forecast period as advancements in hormone-related therapies and targeted treatments for postmenopausal osteoporosis persist.
By Distribution Channel
The hospital pharmacies segment held the largest market share in 2024 of the osteoporosis treatment market, with a 56.15% due to the large number of prescriptions and ready availability of advanced treatment options in hospital settings. The online pharmacies segment is anticipated to be the fastest-growing osteoporosis treatment market during the forecast period due to the expanding digital health ecosystem and growing consumer inclination towards the convenience of shopping online and home delivery.
Need Any Customization Research on Osteoporosis Treatment Market, Enquire Now: https://www.snsinsider.com/enquiry/3337
Regional Insights:
North America dominated the osteoporosis treatment market with a 40.1% market share in 2024, due to established healthcare infrastructure, prominent pharmaceutical companies, and higher prevalence of the disease, especially in geriatric and postmenopausal women.
Asia Pacific osteoporosis treatment market trends are growing the fastest over the forecast period due to the increasing number of elderly populations, increased healthcare spending, and growth in awareness for bone-related disease.
Recent Developments:
- In May 2023, Amgen released new data from a real-world study of close to 500,000 postmenopausal women with osteoporosis who are covered by the U.S. Medicare program. The evidence showed that fracture risk was significantly lowered through treatment with Prolia (denosumab) compared to oral alendronate, a widely used bisphosphonate.
- In November 2023, Teva Pharmaceuticals Inc., the U.S. subsidiary of Teva Pharmaceutical Industries Ltd., announced FDA approval of a U.S. generic version of Forteo (teriparatide). According to the company, the product will be available for commercial sale in the U.S. in a few weeks, broadening access to treatment options for osteoporosis.
Osteoporosis Treatment Market Segmentation Highlights
By Drug Class
- Calcitonin
- Bisphosphonate
- Zoledronic Acid
- Ibandronate
- Alendronate
- Risedronate
- Hormone Replacement Therapy
- RANK ligand (RANKL) Inhibitor
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Selective Estrogen Receptor Modulator (SERMs)
By Route of Administration
- Oral
- Parenteral
By Gender
- Female
- Male
By Distribution Channel
- Hospitals Pharmacies
- Retail Pharmacies & Stores
- Online Pharmacies
Purchase Single User PDF of Osteoporosis Treatment Market Report: https://www.snsinsider.com/checkout/3337
Exclusive Sections of the Report (The USPs):
- EPIDEMIOLOGICAL BURDEN & RISK METRICS – helps you understand the scale of the disease through insights on global patient prevalence, gender-specific distribution, fracture risk assessment, and aging-related epidemiological trends shaping treatment demand.
- PRESCRIPTION & THERAPY ADOPTION TRENDS – helps you track real-world clinical practice by analyzing the shift toward injectable biologics, declining adherence to oral bisphosphonates, combination therapy preferences, and the influence of cost and compliance on drug selection.
- DRUG VOLUME & MARKET GROWTH TRAJECTORY – helps you evaluate long-term demand by examining treatment volume trends from 2020 to 2032, drug-class-specific growth, generic vs branded dynamics, and population-driven shifts in diagnosis and therapy uptake.
- HEALTHCARE SPENDING & ECONOMIC BURDEN INDEX – helps you assess financial sustainability through insights on public vs private funding patterns, evolving reimbursement support, out-of-pocket burden, and the economic impact of osteoporotic fractures.
- EMERGING THERAPY & INNOVATION LANDSCAPE – helps you identify future opportunities by tracking the rise of long-acting injectables, digital adherence and engagement platforms, biosimilar/generic expansion, and pipeline advances such as sclerostin inhibitors.
- PREVENTIVE CARE & EARLY DIAGNOSIS ACCELERATION – helps you uncover growth potential in proactive healthcare strategies, highlighting trends in screening programs and early diagnosis initiatives that reshape long-term treatment volumes.
Related Reports
Orthopedic Devices Market
Bone Densitometers Market
Osteoarthritis Therapeutics Market
Women’s Health Therapeutics Market
Hormone Replacement Therapy Market
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@snsinsider.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.